Hence, the overarching purpose of the present meta-analysis was to pool data from all placebo-controlled RCTs that evaluated AF/AFL outcomes of SGLT2 inhibitors, from which we gained more reliable assessments of the efficacy and safety of specific results overall and in relevant subgroups. This evidence concerns the gene SLC5A2 and atrial fibrillation.